L Otero1, A De Orbegoso, A F Navarro, J Ríos, T Párraga, E Gotuzzo, C Seas, P Van der Stuyft. 1. Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru; Unit of General Epidemiology and Disease Control, Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium.
Abstract
OBJECTIVE: To determine the time from diagnosis to start of multidrug resistant tuberculosis (MDR TB) treatment in Lima, Peru. METHODS: We studied new smear-positive TB adults that were started on MDR TB treatment or that were switched to it between June 2008 and December 2011. RESULTS: Time from the first positive smear to MDR-TB treatment was >30 days in 35% (13/37) of patients. Among the 27% (24/88) of patients that switched to MDR-TB treatment, time from the last dose of a drug-susceptible regimen was >30 days. CONCLUSION: Start of and switching to MDR TB treatment is still delayed.
OBJECTIVE: To determine the time from diagnosis to start of multidrug resistant tuberculosis (MDR TB) treatment in Lima, Peru. METHODS: We studied new smear-positive TB adults that were started on MDR TB treatment or that were switched to it between June 2008 and December 2011. RESULTS: Time from the first positive smear to MDR-TB treatment was >30 days in 35% (13/37) of patients. Among the 27% (24/88) of patients that switched to MDR-TB treatment, time from the last dose of a drug-susceptible regimen was >30 days. CONCLUSION: Start of and switching to MDR TB treatment is still delayed.
Keywords:
Peru; Perú; Pérou; Tiempo hasta el inicio del tratamiento; Tuberculosis; multidrug resistant; multirresistente; multirésistante; temps jusqu'au traitement; time to treatment; tuberculose; tuberculosis
Authors: M Yagui; M T Perales; L Asencios; L Vergara; C Suarez; G Yale; C Salazar; M Saavedra; S Shin; O Ferrousier; P Cegielski Journal: Int J Tuberc Lung Dis Date: 2006-08 Impact factor: 2.373
Authors: Grant Theron; Lynn Zijenah; Duncan Chanda; Petra Clowes; Andrea Rachow; Maia Lesosky; Wilbert Bara; Stanley Mungofa; Madhukar Pai; Michael Hoelscher; David Dowdy; Alex Pym; Peter Mwaba; Peter Mason; Jonny Peter; Keertan Dheda Journal: Lancet Date: 2013-10-28 Impact factor: 79.321
Authors: Kate Clouse; Liesl Page-Shipp; Heather Dansey; Bridgette Moatlhodi; Lesley Scott; Jean Bassett; Wendy Stevens; Ian Sanne; Annelies Van Rie Journal: S Afr Med J Date: 2012-09-07
Authors: Karen R Jacobson; Danie Theron; Emily A Kendall; Molly F Franke; Marinus Barnard; Paul D van Helden; Tommie C Victor; Elizabeth M Streicher; Megan B Murray; Robin M Warren Journal: Clin Infect Dis Date: 2012-10-22 Impact factor: 9.079
Authors: Evan W Orenstein; Sanjay Basu; N Sarita Shah; Jason R Andrews; Gerald H Friedland; Anthony P Moll; Neel R Gandhi; Alison P Galvani Journal: Lancet Infect Dis Date: 2009-03 Impact factor: 25.071
Authors: Colleen F Hanrahan; Susan E Dorman; Linda Erasmus; Hendrik Koornhof; Gerrit Coetzee; Jonathan E Golub Journal: PLoS One Date: 2012-11-30 Impact factor: 3.240
Authors: Sonya S Shin; Martin Yagui; Luis Ascencios; Gloria Yale; Carmen Suarez; Neyda Quispe; Cesar Bonilla; Joaquin Blaya; Allison Taylor; Carmen Contreras; Peter Cegielski Journal: Emerg Infect Dis Date: 2008-05 Impact factor: 6.883
Authors: Francesca Barletta; Larissa Otero; Bouke C de Jong; Tomotada Iwamoto; Kentaro Arikawa; Patrick Van der Stuyft; Stefan Niemann; Matthias Merker; Cécile Uwizeye; Carlos Seas; Leen Rigouts Journal: J Clin Microbiol Date: 2015-03-25 Impact factor: 5.948
Authors: Rebecca C Harris; Louis Grandjean; Laura J Martin; Alexander J P Miller; Joseph-Egre N Nkang; Victoria Allen; Mishal S Khan; Katherine Fielding; David A J Moore Journal: BMC Infect Dis Date: 2016-05-04 Impact factor: 3.090